A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of the TIMI 37 trial

David A. Morrow, Chaim M. Brickman, Sabina A. Murphy, Kenneth Baran, Ricardo Krakover, Harold Dauerman, Sujatha Kumar, Natanya Slomowitz, Laura Grip, Carolyn H. McCabe, Andrew L. Salzman

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of the TIMI 37 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences